Alexander C Egilman
Overview
Explore the profile of Alexander C Egilman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Skydel J, Egilman A, Wallach J, Ramachandran R, Gupta R, Ross J
JAMA Health Forum
. 2022 Aug;
3(5):e221158.
PMID: 35977252
Importance: Accelerated approval by the US Food and Drug Administration (FDA) grants market authorization for drugs based on clinical trials using surrogate end points likely to anticipate a clinical benefit....
12.
Rome B, Egilman A, Kesselheim A
JAMA
. 2022 Jun;
327(21):2145-2147.
PMID: 35670795
No abstract available.
13.
Egilman A, Kapczynski A, McCarthy M, Luxkaranayagam A, Morten C, Herder M, et al.
J Law Med Ethics
. 2021 Oct;
49(3):456-485.
PMID: 34665102
Based on an analysis of relevant laws and policies, regulator data portals, and information requests, we find that clinical data, including clinical study reports, submitted to the European Medicines Agency...
14.
Egilman A, Ross J, Herder M
CMAJ
. 2021 Oct;
193(41):E1616-1618.
PMID: 34663613
No abstract available.
15.
Puthumana J, Egilman A, Ramachandran R, Naushad N, Shah N, Ross J
BMJ Evid Based Med
. 2021 Oct;
27(4):195-198.
PMID: 34635478
No abstract available.
16.
Egilman A, Ross J, Herder M
CMAJ
. 2021 Aug;
193(33):E1305-E1306.
PMID: 34426449
No abstract available.
17.
Long A, Zhang A, Meyer C, Egilman A, Ross J, Wallach J
JAMA Netw Open
. 2021 May;
4(5):e215731.
PMID: 33956134
Importance: Chiral switching, a strategy in which drug manufacturers develop a single-enantiomer formulation of a drug to be substituted for a racemic formulation, allows manufacturers to maintain market exclusivity for...
18.
Zhang A, Puthumana J, Egilman A, Schwartz J, Ross J
J Gen Intern Med
. 2021 Mar;
37(3):700-702.
PMID: 33660209
No abstract available.
19.
Puthumana J, Egilman A, Zhang A, Schwartz J, Ross J
JAMA Intern Med
. 2020 Nov;
181(4):559-560.
PMID: 33170923
No abstract available.
20.
Wallach J, Serghiou S, Chu L, Egilman A, Vasiliou V, Ross J, et al.
BMC Med Res Methodol
. 2020 Mar;
20(1):64.
PMID: 32171256
Background: Among different investigators studying the same exposures and outcomes, there may be a lack of consensus about potential confounders that should be considered as matching, adjustment, or stratification variables...